Beneficial microbes最新文献

{"title":"A double-blind randomised controlled trial assessing the effect of menaquinone producing probiotics on vitamin K status.","authors":"M Muilwijk, S Kremers, L J Schurgers, M Stolaki, S J L Bakker, J W J Beulens","doi":"10.1163/18762891-bja00117","DOIUrl":"https://doi.org/10.1163/18762891-bja00117","url":null,"abstract":"<p><p>This double-blinded randomised controlled trial investigated whether menaquinones (MK) producing probiotics for 12 weeks improve vitamin K status, compared with placebo in 50-75 years old with at least one cardiovascular risk factor. Twenty participants were randomised to either MK-producing probiotics (n = 10) or placebo (n = 10). Plasma dephosphorylated-uncarboxylated matrix gla protein (dp-ucMGP) concentrations were the primary study outcome and determined at baseline, six and twelve weeks by a chemiluminescent InaKtif MGP assay, and analysed by linear mixed models. Secondary outcomes included serum MK-7 and phylloquinone and stool MK-4 to MK-10 and phylloquinone, assessed by linear regression. Three participants dropped out (two placebo, one intervention). Compliance was high; median 98% [IQR 96-99] and 90% [IQR 74-96] sachets used in intervention vs placebo arm. At 6 weeks, dp-ucMGP was significantly lower in the intervention group (-75.69 [95%-CI -128.37; -22.92] pmol/l), but this difference diminished by 12 weeks (-38.63 [95%-CI -94.49; 16.14] pmol/l) due to a reduction in the placebo group. Overall, the mean dp-ucMGP change over 12 weeks favoured the intervention (-59.89 [95%-CI -110.7; -9.187] pmol/l). Statistically significant differences in secondary outcomes included higher serum MK-7, and faecal MK-6 and MK-7 concentrations in the probiotic vs placebo arm (e.g. 4.41 [95%-CI 2.17; 6.65] μg/L for serum MK-7). No other secondary outcomes differed significantly. MK producing probiotics may enhance vitamin K status in older adults at elevated cardiovascular risk. Larger, longer-term studies are needed to assess functional outcomes. The Netherlands Trial Register: NTR7505, 27-09-2018.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-15"},"PeriodicalIF":3.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147715533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation and gut microbiota: A randomised pilot study in Vietnam.","authors":"V Hoang Van, T Dong Van, N Nguyen Bao, U Nguyen Quynh, C Nguyen Thi Linh, C Dao Xuan, T Akiyama","doi":"10.1163/18762891-bja00116","DOIUrl":"https://doi.org/10.1163/18762891-bja00116","url":null,"abstract":"<p><p>Fermented milk containing Lacticaseibacillus paracasei strain Shirota (LcS) has been shown to improve stool consistency in various countries; however, its effect on hard or lumpy stools (HLS) in the Vietnamese population remains unclear. We investigated the effects of LcS-fermented milk on constipated Vietnamese adults with a high prevalence of HLS. In a single-centre, open-label trial, 51 participants with HLS were randomised to receive one bottle per day of fermented milk containing ≥6.5 × 109 cfu of LcS for 4 weeks (probiotic group) or no intervention (control group), followed by a 2-week washout. The primary endpoint was the proportion of participants with HLS (Bristol Stool Form Scale score of 1 or 2) in ≥25% of bowel movements over 4 weeks. Secondary endpoints included total stool frequency, HLS frequency, ideal stool form, and defecation-related symptoms - all recorded in daily diaries. The Chinese Constipation Questionnaire (CCQ) and gut microbiota composition (16S rRNA sequencing) were assessed every 2 weeks. During the intervention, the probiotic group had a significantly lower proportion of participants with HLS in ≥25% of bowel movements compared to controls (odds ratio: 0.00; 95% confidence interval: 0.00-0.16; P = 0.005). The probiotic group also showed increased total stool frequency ( P = 0.001), reduced HLS frequency ( P = 0.035), and fewer participants with CCQ scores ≥5 indicating constipation ( P < 0.001) at 4 weeks. Gut microbiota beta-diversity differed between groups after 2 weeks ( P = 0.031), with reductions in Peptococcaceae, Clostridium_methylpentosum_group, and Clostridia (unclassified at the order level), followed by increases in Lachnospiraceae_UCG-004 at 4 weeks and Lachnospiraceae_ND3007_group post-follow-up ( P < 0.050), suggesting microbial changes linked to constipation improvement. No serious adverse events related to the intervention were observed. These findings support daily LcS-fermented milk as a dietary strategy in Vietnam to manage constipation via gut microbiota modulation. The study was registered at ClinicalTrials.gov (ID: NCT05982743).</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-14"},"PeriodicalIF":3.1,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of probiotics supplementation on serum markers of oxidative stress in relapsing-remitting multiple sclerosis: a randomised, double-blind, placebo-controlled clinical trial.","authors":"N Mohy, S Sanaie, S Rahnemayan, M Yousefi, M Talebi, A Naseri","doi":"10.1163/18762891-bja00115","DOIUrl":"https://doi.org/10.1163/18762891-bja00115","url":null,"abstract":"<p><p>Oxidative stress is a significant contributor to neuronal damage in multiple sclerosis (MS), marked by an imbalance in reactive oxygen species and antioxidant defences. Probiotics may modulate oxidative stress and improve antioxidant levels. This double-blind, randomised, placebo-controlled clinical trial aimed to evaluate the effects of probiotics supplementation on serum oxidative stress markers and endogenous antioxidants in patients with relapsing-remitting MS (RRMS). Ninety RRMS patients with expanded disability status scale [EDSS] < 4 were randomised into two groups: a probiotics group (Lactocare®) and a placebo group, and received the interventions twice daily for four months. Serum levels of oxidative stress markers (malondialdehyde [MDA]), endogenous antioxidants (glutathione peroxidase [GPx] activity, superoxide dismutase [SOD], catalase activity [CAT], glutathione [GSH]), and total antioxidant capacity (TAC) were measured at baseline and post-treatment. Fifty-five patients, including 26 patients in the probiotic group and 29 patients in the placebo group, completed the study. Both groups showed significant within-group improvements in GPx activity, SOD, and GSH levels, as well as reductions in MDA levels ( P < 0.05); however, no significant between-group differences were found for any markers ( P > 0.05). TAC and CAT levels remained unchanged in both groups. Findings of this study did not support the evidence for antioxidant effects of probiotics supplementation in RRMS patients, and its effects on oxidative stress markers in RRMS patients are found to be comparable to placebo. Iranian Registry of Clinical Trials: IRCT20220713055465N2, registration date: 2023.5.9.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-8"},"PeriodicalIF":3.1,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactiplantibacillus plantarum LP4 alleviates alcoholic liver disease in C57BL/6 mice.","authors":"L Liu, X Tian, S Hao, Y Zhang, N Zhang, X Xing, B Nan, Y Wang","doi":"10.1163/18762891-bja00114","DOIUrl":"https://doi.org/10.1163/18762891-bja00114","url":null,"abstract":"<p><p>Chronic alcoholism can result in alcoholic liver disease. Current treatment methods for alcoholic liver injury primarily include abstinence, drug therapy, and surgical treatment. However, these methods have their own shortcomings - abstinence does not cure alcoholic liver disease, drug therapy can produce negative side effects, and surgical treatment is often accompanied by risks, specifically liver rejection. Therefore, it is especially important to find a safe and effective method to ameliorate alcoholic liver disease. Probiotics, as natural microorganisms in the human intestine, can effectively alleviate alcoholic liver disease due to their unique properties. While Lactiplantibacillus (Lpb.) plantarum, a representative strain of probiotics, has been shown to exert beneficial effects against alcoholic liver injury, the underlying mechanism is unclear. In this study, a murine model of alcoholic liver injury was established in C57BL/6 mice by feeding mice a Lieber-DeCarli diet for 2 weeks. This model was then utilised to assess the potential protective mechanism of Lpb. plantarum LP4. The results demonstrated that Lpb. plantarum LP4 could significantly decrease pro-inflammatory cytokines in serum and liver, thereby reducing the inflammatory response. Furthermore, treatment with Lpb. plantarum LP4 inhibited inflammation and oxidative stress in the liver by modulating several signalling pathways. In addition, Lpb. plantarum LP4 also prevented endotoxin-induced hepatic injury by protecting the integrity of the intestinal barrier. In conclusion, Lpb. plantarum LP4 can effectively alleviate alcoholic liver injury in C57BL/6 mice.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and the gut microbiota in the Middle East: a cross-cultural study of Lebanese and Emirati adults.","authors":"M Ali Ahmad, M Abou-Samra, E Blaak, M Karavetian, C Ayoub Moubareck, K Venema","doi":"10.1163/18762891-bja00111","DOIUrl":"https://doi.org/10.1163/18762891-bja00111","url":null,"abstract":"<p><p>Obesity is a growing public health concern in the Middle East and North Africa (MENA) region, yet limited research has explored how gut microbiota varies between Arab populations. This study compared the gut microbiota composition and diversity of Emirati and Lebanese adults with obesity and assessed the role of age and nationality in shaping microbial variation. A total of 43 Emirati and 30 Lebanese individuals with obesity (body mass index (BMI) ≥35 kg/m2) were recruited. Participants provided anthropometric and biochemical data, dietary records, and stool samples for 16S rRNA sequencing. The analysis revealed significantly higher BMI, weight, and fat mass in Emirati participants, while Lebanese individuals reported higher fibre intake. Taxonomic profiling showed higher relative abundances of Pseudomonadota, Mycoplasmatota, Cyanobacteriota, and Lentisphaerota in the Lebanese group, whereas Bacteroidota was more abundant among Emiratis. Lebanese participants also exhibited significantly greater microbial alpha-diversity. Beta-diversity analysis confirmed clear distinctions in microbial community structure between the two groups. Linear Discriminant Analysis Effect Size (LefSe) (LDA score >10log2) and regression models ( P < 0.05) identified specific bacterial genera associated with nationality, although these associations were attenuated after adjusting for age. These findings suggest that gut microbiota in Arab populations is influenced by demographic, dietary, and environmental factors, emphasising the need for culturally tailored microbiota-based strategies to manage obesity and related metabolic conditions.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-22"},"PeriodicalIF":3.1,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal health: results of a randomised, double-blind, placebo-controlled pilot study.","authors":"K Sorensen, S Khanna, A Porwal, B L Dharmendra, P Soni, D Siddavaram, C Holz, S Jadhav","doi":"10.1163/18762891-bja00113","DOIUrl":"https://doi.org/10.1163/18762891-bja00113","url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) is a chronic functional disorder characterised by abdominal pain and altered bowel habits. The most prevalent subtype is diarrhoea-predominant IBS (IBS-D). The combination of Bacillus subtilis HU58 and Heyndrickxia faecalis (formerly Bacillus coagulans) SC208 has previously exerted positive effects in people with antibiotic-associated diarrhoea and infective diarrhoea. The present multicentre study conducted in India aimed to evaluate the effectiveness and safety of the dual-strain probiotic in adults (18-65 years) with IBS-D. In this randomised, double-blind, placebo-controlled pilot study, 61 participants were recruited and assessed for changes in abdominal pain intensity (Numeric Rating Scale, NRS) and stool consistency (Bristol Stool Form Scale, BSFS) over a 4-week intervention period, with secondary outcomes including responder rates for IBS Global Assessment of Improvement (IBS-GAI) and perceived stress (Perceived Stress Scale, PSS). The probiotic group showed significantly higher overall responder rates for both abdominal pain and stool consistency ( P = 0.003) compared to the placebo group. Significant improvements were observed in abdominal pain ( P = 0.003) and stool consistency ( P = 0.035) scores in the probiotic versus placebo group from baseline to end of intervention. IBS-GAI responder rates were significantly higher among the probiotic versus placebo group ( P = 0.017) whilst perceived stress scores did not differ significantly between groups. In conclusion, supplementation with B. subtilis HU58 and H. faecalis SC208 for 4 weeks was safe and effective in improving stool consistency and abdominal pain in individuals with IBS-D, supporting its potential for symptom management in IBS-D. The trial is registered at https://ctri.nic.in/Clinicaltrials (CTRI/2022/07/044154).</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-12"},"PeriodicalIF":3.1,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted detection of microbes in synbiotic medical foods SBD111 and SBD121 to evaluate gut persistence: a randomised, open label trial.","authors":"K J Miller, I M Wolff, L A Montes de Oca Valeriano, M J Soto-Giron, S Jangi, E M Schott, M R Charbonneau, A E Ballok, G V Toledo","doi":"10.1163/18762891-bja00109","DOIUrl":"https://doi.org/10.1163/18762891-bja00109","url":null,"abstract":"<p><p>The viability and persistence of orally administered microbes in the human gut are essential to their biological function. We previously described the development of two synbiotic medical foods, SBD111 and SBD121, each comprising four food-derived microbial strains and prebiotic fibres for the dietary management of postmenopausal bone loss and rheumatoid arthritis, respectively. Here, we report a randomised, open-label clinical study examining gut persistence of SBD111 and SBD121 microbes by testing faecal samples from healthy adults following administration for seven days. Thirty-eight participants, aged 18-64 years with a body mass index (BMI) of 18.5-35 kg/m2, were randomised to receive one of the two synbiotic medical foods daily for one week, followed by a four-week monitoring period. Employing quantitative PCR (qPCR), shotgun metagenomics, and culture-based assays, we evaluated the presence and viability of the microbial strains comprising each synbiotic medical food during and after administration. SBD111 and SBD121 were well-tolerated with minimal adverse events reported. Strains were detected in over 80% of participants during the administration period, with strain abundance peaking in the first week. Persistence in the follow-up period varied by strain and detection method. The microbial strains were detected by qPCR and metagenomic sequencing for a median of seven days and three days during the follow-up period, respectively. However, Bacillus amyloliquefaciens was consistently detected for seven days by both methods. Culture-based assays confirmed the presence of viable strains from both synbiotic medical foods in stool samples up to one-week post-consumption. Faecal metagenome diversity and metabolic functional potential remained stable throughout the administration and follow-up periods. Collectively, these results establish that SBD111 and SBD121 deliver viable microbes that transiently persist in the gut, reinforcing their promise for safe and targeted dietary interventions and highlighting the value of multi-platform detection strategies for comprehensive microbial persistence assessment. This trial, funded by Sōlarea biō, is registered at ClinicalTrials.gov (NCT06614166).</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146163901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of antioxidant activity of novel potential probiotic cocktail in mice model of gut inflammation via oxidative stress-related pathways.","authors":"N Rezaie, S Aghamohammad, F Bagheri-Amiri, S Khatami, M Talebi, A Sohrabi, M R Pourshafie, M Rohani","doi":"10.1163/18762891-bja00112","DOIUrl":"https://doi.org/10.1163/18762891-bja00112","url":null,"abstract":"<p><p>Oxidative stress plays a key role in colitis, a type of Inflammatory Bowel Disease, particularly when associated with a high-fat diet (HFD). Probiotics are known to alleviate inflammation through multiple mechanisms. This study aimed to evaluate the efficacy of a potential probiotic mixture with high antioxidant activity in attenuating colitis in mice fed either a normal diet (ND) or an HFD, with a focus on oxidative stress-related pathways. Eighty-eight Lactobacillus and Bifidobacterium strains isolated from healthy human faeces and milk were screened for antioxidant capacity. The six most active strains were selected to formulate a probiotic cocktail. Male C57BL/6 mice were divided into ND and HFD groups, each receiving dextran sulphate sodium (DSS) alone or combined with the probiotic cocktail. Disease indices, histopathology, and the expression of genes related to NF-kB and Nrf2 signalling, as well as oxidative and inflammatory markers, were assessed. Mice treated with the probiotic cocktail showed significant attenuation of DSS-induced colitis, evidenced by lower Disease Activity Index and pathological scores, and improved intestinal morphology ( P < 0.05). Both dietary groups exhibited elevated antioxidant enzyme activity and anti-inflammatory cytokine levels ( P < 0.05). The modulation of Nrf2 and NF-kB-related gene expression was more pronounced in ND-fed mice. The findings suggest that this novel probiotic cocktail can effectively alleviate colitis symptoms, likely by regulating oxidative stress and inflammatory pathways. Its incorporation as an adjunct therapy, particularly alongside a balanced diet, may offer a promising strategy for colitis management.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pragmatic approach to integrate evidence-based medicine and personalized medicine: the example of personalized microbiome-targeting interventions.","authors":"D Zeilstra, A A Te Velde, G Remmers, I Besseling-van der Vaart, R J Brummer, A D Kraneveld","doi":"10.1163/18762891-bja00110","DOIUrl":"https://doi.org/10.1163/18762891-bja00110","url":null,"abstract":"<p><p>Health care practitioners (HCPs) strive to provide the best medical care for each individual patient. The question as to what constitutes 'the best' does, however, not have a single straightforward answer. Evidence-based Medicine (EBM) and Personalized Medicine (PM) are two paradigms that have emerged as means to improve intervention selection. Both paradigms have their own strengths and weaknesses that affect their use in clinical decision-making. In this review we discuss the strengths and weaknesses from the patient's and HCP perspective: how to find the best intervention for a particular patient. We review methodological and practical aspects, and zoom out from the scientific level to the epistemological level to integrate EBM and PM. Both EBM and PM are based on a realist worldview and by adopting a pragmatist worldview the strengths of both paradigms can be combined. We apply this pragmatic approach, called Evidence-based Personalized Medicine (EBPM), to microbiome-targeting interventions. The example EBPM implementation uses four steps. First, it allows HCPs to provide information (clinical diagnosis, complaints, patient needs, laboratory measures) about an individual patient. Second, it uses a GRADE-based system to grade evidence of specific intervention components. Next, it combines the patient profile data and preferences with the graded evidence, to come to a suggestion for a personalized intervention. Finally, this method enables gathering of treatment effects providing feedback into the system and further improve suggestions for future patients.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-25"},"PeriodicalIF":3.1,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146163889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating therapeutic efficacy of Lactobacillus salivarius GZLC1 on colitis by examining its effects on intestinal fungi, antioxidant capacity, and inflammatory response in mice.","authors":"J Ma, D Wu, M Liu, C Xu, Q He, M Wang, F A Kiani, M S Rafiq, K Mehmood, D Fouad, F S Ataya, K Li","doi":"10.1163/18762891-bja00108","DOIUrl":"https://doi.org/10.1163/18762891-bja00108","url":null,"abstract":"<p><p>We investigated the therapeutic potential of Lactobacillus salivarius in colitis mice, and the mice were randomly allocated into three groups with each consisting of 10 mice (n = 10): a control group (CSG), a DSS-induced colitis model group (DSG), and a L. salivarius intervention group (LSG). The intervention group received daily oral administration of L. salivarius for seven consecutive days. Compared to the DSS model group, mice receiving L. salivarius exhibited significantly reduced weight loss, lower DAI scores, lessened colon shortening, and improved histopathological profiles, indicating a substantial reduction in inflammatory damage. Additionally, ITS sequencing revealed that L. salivarius significantly influenced the composition of the intestinal fungal community, decreasing the abundance of pathogenic fungi, such as Candida species, by approximately 40%, and restoring fungal homeostasis by reducing the Basidiomycota/Ascomycota ratio. Moreover, L. salivarius effectively alleviated DSS-induced oxidative stress by lowering serum MDA levels while enhancing the activity of SOD and GSH-Px. Furthermore, the probiotic intervention resulted in 30-40% reduction in pro-inflammatory factors (TNF-α, IL-6, and IL-1β) and an increase in the anti-inflammatory factor IL-10 levels, suggesting a pronounced anti-inflammatory effect. In conclusion, L. salivarius exerts significant protective effects against DSS-induced colitis by modulating the gut fungal community, mitigating oxidative stress, and suppressing inflammatory responses. This study is novel in that few probiotic studies have investigated the impact of L. salivarius on gut fungi in DSS-induced colitis. These findings highlight its potential as a therapeutic candidate for managing inflammatory bowel disease.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}